BCL2 and lung carcinoma: To test whether direct activation of the proapoptotic activity of Bak combined with inhibition of the antiapoptotic function of Bcl2 achieves synergistic effects in lung cancer therapy, a SCLC cell line (DMS53) and NSCLC cell line (H460) that express endogenous Bcl2 and Bak were treated with venetoclax in combination with BKA-073 for 16h and 72h, followed by analysis of dynamic BH3 profiling and apoptosis, respectively.